's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To...

's Daily Biotech Pulse: PTC To Buy Agilis, Zynerba To...


PTC Therapeutics, Inc. announced an agreement to buy Agilis Biotherapeutics, which is developing a gene therapy platform for rare monogenic diseases affecting the central nervous system, for an upfront payment of $50 million in cash and about $150 million in PTC common stock. In addition, Agilis stands to receive up to $745 million in milestone payments.



from Biotech News